Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria

NCT00295581 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00295581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00295581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Completed
Start date
March 7, 2005
Completion date
June 17, 2008
Enrollment
0
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum, plasmodium vivax malaria